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Abstract 
Background: Traditional mistletoe (Viscum album L.) therapy has been frequently used in 
patients with cancer in Europe. The different mistletoe formulations available for oncological use 
are Iscador®, Iscucin®, AbnovaViscum®, and Lektinol®, as well as Helixor®, which may 
improve therapeutic outcomes following intravenous (i.v.) administration and therefore, is 
becoming more commonly used.  
Method: I conducted an observational study in four different University Hospital Centers and 
the frequency of adverse drug reactions (ADRs) induced by the i.v. infusion of Helixor® was 
determined.  
Result: of the 108 patients with gynecological cancer who received i.v. infusions of Helixor®, 
10 (9.3%) reported mild ADRs, and no serious ADRs were reported.  
Conclusion: Therefore, i.v. infusion of Helixor® was determined to be safe, and prospective 
efficacy studies are recommended. 
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1. Introduction 
 
Mistletoe (Viscum album L.), a plant with a partially woody stem, is a semi-parasite that lives 
epiphytically on the branches of a variety of deciduous and coniferous trees [1]. The stems and 
leaves of mistletoe are used as herbal drugs, and various commercially available preparations are 
formulated from the crude mistletoe plant material [1]. Mistletoe extracts are complex 
multicomponent herbal preparations that contain various biologically active substances such as 
mistletoe lectins (ML), viscotoxins, amino acids, flavonoids, phenylpropanoids, triterpenes, 
phytosterol, alkaloids, polyalcohols, and polysaccharides, the content of which may vary 
depending on harvest time, species of the host tree, and manufacturing process [2] [3]. The 
different fractions and components exhibit varying activities including cytotoxic, antineoplastic, 
and immunomodulatory, which appear to be dose-dependent [4].  
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Mistletoe extracts are the most frequently prescribed complementary therapies for patients with 
cancer in Europe, especially in Germany, Switzerland, and Austria [5]. Mistletoe preparations 
such as AbnobaVISCUM
®
, Helixor
®
, Iscador
®
, and Iscucin
®
 are most commonly administered 
as subcutaneous (s.c.) injections starting at a low dose, which is gradually increased over time 
based on individual patient responses [5]. Increasingly, mistletoe preparations are also 
administered at high initial doses as s.c. injections, intravenous (i.v.) infusions, or intratumorally 
(i.t.), depending on the location of the tumor, disease stage, and the experience of the physician 
[6]. There appears to be accumulating evidence of the safety, improvement of the quality of life 
(QOL), and reduction in adverse drug reactions (ADRs) to conventional therapies, associated 
with traditional s.c. mistletoe therapy [5].  
 
To date, no widely accepted treatment scheme is available for mistletoe preparations, although 
s.c. injections of the different preparations twice a week are frequently used [1]. The PubMed 
database alone lists more than 1,200 citations for “mistletoe” with approximately 50 new entries 
each year [6]. A multitude of laboratory-based studies demonstrated immune stimulation, 
cytotoxicity, proapoptotic effects, antiangiogenesis, and DNA stabilization while animal 
experiments have found tumor-reducing effects [7].   
 
In recent years, the number and quality of clinical research studies on mistletoe therapy reporting 
improved patient outcomes have increased, including studies of its coadministration with 
chemotherapeutic agents to reduce adverse effects and improve the QOL of patients with breast, 
ovarian, and lung cancers [8].  
 
Mistletoe extracts have shown a wide range of immunological effects including increased 
macrophage activity, proliferation of neutrophils, enhanced C-reactive protein levels, cytotoxic 
complement activation, and NK-cell cytotoxicity by inducing CD3+CD4+ T cells to release 
interferon (IFN)-γ [9] [10].  
 
Helixor® is the pure, sterile-filtered, aqueous fresh extract of the plant V. album L. (white-
berried mistletoe). Standardized production processes as well as continuous physical, chemical, 
and biological quality control, including the assessment of cytotoxic effects on MOLT 4 
leukemia cells to determine the biological activity of the mistletoe product, guarantee a 
consistent batch-to-batch quality. The most recent, high-quality studies have provided evidence 
of improved QOL and tolerability of chemotherapy during concomitant supportive therapy with 
Helixor® products. Furthermore, a recent study showed that there are no indications that these 
effects exert a negative influence on conventional standard oncological therapy. 
 
This study investigated potential adverse drug reactions (ADRs) of Helixor® administered to 
patients with cancer who visited four different hospitals during the period from March 2014 to 
August 2015. 
 
2. Materials and Methods  
 
A multicenter, observational study was carried out in which Helixor
®
 was coadministered to 
patients who had been treated for gynecological cancer at four different hospitals from March 
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2014 to August 2015 and subsequently came to our hospital for radiology therapy or post-
surgery anticancer treatment.  
 
The administration frequency, duration of therapy, and ADRs were investigated for all 108 
patients administered Helixor
® 
i.v. The numbers of ADRs experienced per person were 
determined while their management and outcome were summarized. To identify the potential 
risks of experiencing an ADR, the doses and preparations that induced ADRs were considered in 
relation to those the patients were exposed to. 
 
3. Results 
 
A total of 108 patients with gynecological cancers who received i.v. Helixor
® 
injections were 
examined.  
 
As shown in Table 1, ovarian cancer was dominant, and one patient had vaginal cancer. The 
analysis of the treatment frequency showed that Helixor
® 
was administered once a week, starting 
with an initial dose of 100 mg, and the majority of patients (74) received it more than 20 times 
(Table 1). Helixor
® 
doses ranged from 100 to 900 mg with a median of 500 mg (Figure 1). 
Furthermore, most of the patients (73) used Helixor
® 
for over 1 month and less than 6 months 
while 23 patients used it for more than 6 months (Table 2). In general, Helixor
® 
was 
administered during chemotherapy (Table 2, n=73), and 18 patients used other forms of 
treatment during the cancer therapy. ADRs were hardly detected, although occasional allergic or 
systemic urticarial reactions occurred at the injection sites, and headaches, as well as an increase 
in liver function tests, were observed (Table 3).   
 
Table 1: Patient cancer types 
Cancer type Patients (n) Percentage (%) 
Cervical 29 27 
Ovarian 60 59 
Endometrial 13 12 
Peritoneal 3 3 
Vaginal 1 1 
Tubal 2 2 
 
Figure 1: Intravenous (i.v.) Helixor
®
 doses 
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Table 2: Characteristics of intravenous (i.v.) Helixor
® 
therapy 
Characteristics Patients (n) 
Application frequency   
      <10 applications    
      10-15 applications 
25 
6 
      16-20 applications 3 
>20 applications 74 
Duration of therapy  
      <1month  12 
      1-6 month 73 
      >6month  23 
Combined therapy  
     Chemotherapy 73 
     Radiation therapy 0 
     Chemotherapy plus Radiation therapy 17 
     Others*  18 
 
*Including immunotherapy, bisphosphonate, signal transduction inhibitors, and hormonal 
therapy. 
 
Table 3: Adverse drug reactions (ADRs) attributable to intravenous (i.v.) 
Affected system/organ Preferred term Total patients (n) Incidence (%) 
Gastrointestinal  Nausea/vomiting 0 0 
 Elevated liver function test 2 2 
 Generalized edema 1 1 
Skin and subcutaneous Injection site allergy 1 1 
tissues Systemic urticaria 2 2 
 Hypersensitivity  0 0 
Others  Headache  3 3 
 Myalgia 0 0 
 Fatigue 0 0 
 Dizziness  1 1 
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4. Discussion 
 
The importance of integrative medicine in oncological care is increasing based on the growth of 
the evidence supporting its use [6]. In central Europe, white-berried mistletoe (V. album) 
preparations are not only are one of the most common types of treatments used in integrative 
medicine, but it is also one of the most commonly prescribed cancer treatments in Germany [6]. 
By 2017, mistletoe preparations will have been used in the treatment of patients with cancer for 
100 years. Mistletoe is a historical folk remedy, and the Dutch physician Ita Wegman was the 
first to use it in the field of oncology as a mistletoe extract for the treatment of a patient with 
breast cancer following a recommendation by Rudolf Steiner [6]. The constituents of the 
mistletoe berry include lectins, viscotoxins, glycoproteins, oligo- and polysaccharides, and 
membrane lipids [6]. Recent evidence of the potent anti-inflammatory effect of V. album via 
selective inhibition of cyclooxygenase (COX-2) protein expression provides a further rationale 
for an antitumor role of mistletoe considering the close relationship between cancer and 
inflammation [11]. Recently, there has been an increase in the number and quality of clinical 
research studies on mistletoe therapy reporting improved patient outcomes.  
 
After several years of clinical testing, Helixor® products were registered in Germany in 1976 
according to German drug legislation (Arzneimittelgesetz, AMG), followed by marketing 
authorization in February 1982. Thus, it was the first mistletoe product authorized for 
subcutaneous injection in Germany. Currently, Helixor® mistletoe products have been 
authorized or registered in Austria, Switzerland, Luxembourg, Sweden, Finland, Latvia, 
Lithuania, Korea, China, Russia, Chile, Peru, and Canada. The efficacy and safety of Helixor® 
was reported in 24 clinical studies and numerous case reports, included in a positive monograph 
published by the Commission C of the German Department of Public Health. Furthermore, there 
is increasing evidence supporting the safety, improvement of QOL, and reduction of adverse 
drug reactions (ADRs) to conventional therapies, associated with traditional s.c. mistletoe 
therapy [5]. However, it has been suggested that high-dose i.v. mistletoe infusions might be even 
more effective and reduce the risk of tumor metastasis or recurrence, possibly by modulating the 
immune system and antiangiogenesis effects [5]. In this study, the Helixor® treatment was 
administered i.v, and no specific concerns were observed other than mild ADRs. Finally, the 
collective results of this study suggest that Helixor® therapy is safe and effective for use as an 
adjuvant therapy in patients with gynecological cancers.  
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